Fig. 4: Statistical comparison with our previous monkey trial.

A previous monkey trial from our group that employed no drug treatment in four monkeys (study # IS-160) was compared to the current monkey trial that employed transient treatment with rapamycin in five monkeys (study # IS-218). Both trials utilized the same AAV9-C-rh 3BNC117 stock at the same dose of 0.2 × 10¹³ GC/kg in naive rhesus monkeys. The levels of C-rh 3BNC117 in serum were compared among the two trials at weeks 2, 4, and 17/16 post AAV9 administration. Week 17 in IS-160 was the latest time point available and compared to the closest time point available in IS-218, which was week 16 post AAV9 (week 4 post rapamycin cessation). Data are presented as mean values ± SD; mean comparison of the historical control group (black circles, n = 4 biological samples) with the rapamycin treatment group (black squares, n = 5 biological samples) using the unpaired t-test (two-tailed) with Welch’s correction, with P ≤ 0.05 (*), P ≤ 0.01 (**), and P ≤ 0.001 (***) indicating statistical significance. Source data are provided as a Source Data file.